MX9102110A - Muteina de factor de necrosis tumoral humano o una sal farmaceuticamente aceptable de la misma,procedimiento para su preparacion y composicion farmaceutica que la contiene - Google Patents

Muteina de factor de necrosis tumoral humano o una sal farmaceuticamente aceptable de la misma,procedimiento para su preparacion y composicion farmaceutica que la contiene

Info

Publication number
MX9102110A
MX9102110A MX9102110A MX9102110A MX9102110A MX 9102110 A MX9102110 A MX 9102110A MX 9102110 A MX9102110 A MX 9102110A MX 9102110 A MX9102110 A MX 9102110A MX 9102110 A MX9102110 A MX 9102110A
Authority
MX
Mexico
Prior art keywords
mutein
factor
procedure
preparation
pharmaceutically acceptable
Prior art date
Application number
MX9102110A
Other languages
English (en)
Inventor
Walter Fiers
Jan Tavernier
Xaveer Van Ostade
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX9102110A publication Critical patent/MX9102110A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX9102110A 1990-11-21 1991-11-18 Muteina de factor de necrosis tumoral humano o una sal farmaceuticamente aceptable de la misma,procedimiento para su preparacion y composicion farmaceutica que la contiene MX9102110A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP90810901 1990-11-21

Publications (1)

Publication Number Publication Date
MX9102110A true MX9102110A (es) 1992-07-08

Family

ID=8205969

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9102110A MX9102110A (es) 1990-11-21 1991-11-18 Muteina de factor de necrosis tumoral humano o una sal farmaceuticamente aceptable de la misma,procedimiento para su preparacion y composicion farmaceutica que la contiene

Country Status (17)

Country Link
US (2) US5422104A (es)
EP (1) EP0486908A3 (es)
JP (1) JPH06256395A (es)
AR (1) AR245783A1 (es)
AU (1) AU655948B2 (es)
CA (1) CA2055168A1 (es)
FI (1) FI915379A (es)
HU (1) HUT62034A (es)
IE (1) IE914035A1 (es)
IL (1) IL100062A0 (es)
MC (1) MC2300A1 (es)
MX (1) MX9102110A (es)
NO (1) NO914541L (es)
NZ (1) NZ240595A (es)
PT (1) PT99560A (es)
UY (1) UY23327A1 (es)
ZA (1) ZA919035B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK376492A3 (en) * 1992-04-02 1995-06-07 Hoffmann La Roche Tnf - muteins and method of their production
CA2119089A1 (en) * 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
EP1069917A4 (en) * 1998-03-20 2005-02-09 Genzyme Corp NEW COMPLEMENTARY PAIRS OF RECEPTORS / LIGANDS AND ADOPTIVE IMMUNOTHERAPY USING THE SAME
ES2267593T3 (es) * 2000-02-16 2007-03-16 Genentech, Inc. Anticuerpos anti-april y celulas hibridomas.
US7446174B2 (en) 2001-03-02 2008-11-04 Xencor, Inc. Protein based TNF-α variants for the treatment of TNF-α related disorders
US7662367B2 (en) 2000-03-02 2010-02-16 Xencor, Inc. Pharmaceutical compositions for the treatment of TNF-α related disorders
US7056695B2 (en) 2000-03-02 2006-06-06 Xencor TNF-α variants
US7244823B2 (en) * 2000-03-02 2007-07-17 Xencor TNF-alpha variants proteins for the treatment of TNF-alpha related disorders
US20070172449A1 (en) * 2000-03-02 2007-07-26 Xencor, Inc. TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERS
US7687461B2 (en) 2000-03-02 2010-03-30 Xencor, Inc. Treatment of TNF-α related disorders with TNF-α variant proteins
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
US6579522B1 (en) 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
MXPA04001050A (es) * 2001-08-03 2004-07-08 Genentech Inc Polipeptidos tacis y br3 y usos de los mismos.
US20030086903A1 (en) * 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
MXPA05000940A (es) * 2002-07-25 2005-05-16 Genentech Inc Anticuerpos taci y su uso.
RU2377253C2 (ru) * 2002-12-02 2009-12-27 Амген Фремонт,Инк. Антитела, специфичные к фактору некроза опухолей, и их применение
PT1631313E (pt) * 2003-06-05 2015-07-02 Genentech Inc Terapêutica de combinação para distúrbios de células b
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
EP2168603A1 (en) * 2003-11-14 2010-03-31 GenVec, Inc. Therapeutic regimen for treating cancer
TW200526780A (en) 2004-01-06 2005-08-16 Hayashibara Biochem Lab TNF antagonists and TNF inhibitors comprising the same as the active ingredient
EP1598075A1 (en) * 2004-05-21 2005-11-23 LEK Pharmaceuticals d.d. Process for the isolation and / or purification of proteins
GB0425972D0 (en) 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
AU2006203850A1 (en) * 2005-01-10 2006-07-13 Research Development Foundation Targeted chimeric molecules for cancer therapy
CA2629306A1 (en) * 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
WO2008127515A1 (en) * 2007-03-01 2008-10-23 Cytologic, Inc. Compositions and method for enhancing immune responses in mammals
US11535673B2 (en) * 2007-04-05 2022-12-27 President and Fellows of Harvard CoHege Chimeric activators: quantitatively designed protein therapeutics and uses thereof
US9605844B2 (en) * 2009-09-01 2017-03-28 Cree, Inc. Lighting device with heat dissipation elements
JP6367836B2 (ja) 2013-02-07 2018-08-01 ザ ジェネラル ホスピタル コーポレイション Ｔ制御性細胞の増殖または枯渇方法
WO2015168474A1 (en) 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
ES2893249T3 (es) 2016-11-09 2022-02-08 Philogen Spa Inmunoconjugados que comprenden IL-2, anticuerpo anti-fibronectina y TNF-alfa mutante
CA3193273A1 (en) 2020-08-27 2022-03-03 Enosi Therapeutics Corporation Methods and compositions to treat autoimmune diseases and cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650674A (en) * 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
GR851626B (es) * 1984-07-05 1985-11-26 Genentech Inc
DE3750056T2 (de) * 1986-06-20 1995-04-06 Dainippon Pharmaceutical Co Polypeptid-Mutanten des menschlichen TNF und für diese Mutanten codierende DNS.
JPH07106158B2 (ja) * 1986-12-04 1995-11-15 サントリー株式会社 抗腫瘍活性を有する新規ポリペプチドおよびその製造法
AU1346488A (en) * 1987-02-26 1988-09-26 Cetus Corporation Arginine-depleted human tumor necrosis factor
JPS63291590A (ja) * 1987-05-25 1988-11-29 Teijin Ltd 新規生理活性ポリペプチド
DE3843534A1 (de) * 1988-12-23 1990-07-12 Basf Ag Neue tnf-polypeptide

Also Published As

Publication number Publication date
AR245783A1 (es) 1994-02-28
JPH06256395A (ja) 1994-09-13
PT99560A (pt) 1992-10-30
FI915379A (fi) 1992-05-22
IL100062A0 (en) 1992-08-18
US5652353A (en) 1997-07-29
UY23327A1 (es) 1992-05-19
AU8791591A (en) 1992-05-28
NZ240595A (en) 1994-09-27
EP0486908A3 (en) 1992-11-19
NO914541L (no) 1992-05-22
HUT62034A (en) 1993-03-29
MC2300A1 (fr) 1993-09-06
ZA919035B (en) 1992-08-26
FI915379A0 (fi) 1991-11-14
HU913595D0 (en) 1992-01-28
EP0486908A2 (en) 1992-05-27
IE914035A1 (en) 1992-06-03
NO914541D0 (no) 1991-11-20
US5422104A (en) 1995-06-06
AU655948B2 (en) 1995-01-19
CA2055168A1 (en) 1992-05-22

Similar Documents

Publication Publication Date Title
MX9102110A (es) Muteina de factor de necrosis tumoral humano o una sal farmaceuticamente aceptable de la misma,procedimiento para su preparacion y composicion farmaceutica que la contiene
ITMI920528A0 (it) 14-beta idrossi-10-de acetil-baccatina iii, suoi derivati, loro preparazione ed impiego terapeutico
ES2080307T3 (es) Composiciones farmaceuticas.
MX9202290A (es) Nuevos derivados de tiopiranopirrol y procedimiento para su preparacion.
BR9502797A (pt) Complexos de análogo de insulina-protamina suas formulações farmaceuticas parenterais processos para preparação dos ditos análogos e das formulações farmacêuticas e cristais de insulina-protamina
BR9610248A (pt) Composto composição farmacêutica processos para o tratamento da dor e para a preparação de um composto e uso do composto
ITMI950529A0 (it) Composizioni farmaceutiche e procedimento per la loro preparazione
DE69107946D1 (de) Adhäsive Präparation zur Förderung der Regenierung verletzter Nerven und klebende pharmazeutische Zubereitungen dafür.
BR9510302A (pt) Forma de dosagem farmacêutical de liberação controlada método para tratamento sintomático da tosse método para preparar uma forma de dosagem farmacêutica de liberação controlada composição para uso no tratamento sintomático da tosse e aplicação de uma forma dosagem de moguisteina de liberação controlada
IL105170A0 (en) Human tumor necrosis factor muteins,their preparation and pharmaceutical compositions containing them
MX22877A (es) Procedimiento para la preparacion de pirimidas, producto obtenido y composicion farmaceutica que lo incluye
ITRM920412A1 (it) Eteroprostanoidi, procedimento per la loro preparazione e loro impiego terapeutico.
EE03663B1 (et) Rinnavähi vältimise meetod, farmatseutiline preparaat ja toode ning toimeaine kasutamine
NO943288D0 (no) Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
MX9207620A (es) Derivados de bencenmetanamina a-substituidos y procedimiento para su preparacion.
IT1229491B (it) Derivati della 1,2,5,6-tetraidropiridina, loro procedimento di preparazione e loro impiego come sostanze medicinali
MX9100357A (es) Composiciones farmaceuticas estabilizadas y procedimiento para su preparacion
ITMI911470A0 (it) N-(5-tioxo-l-prolil)-l-cisteina e suoi derivati, loro preparazione ed impiego terapeutico
MX9100742A (es) Composicion farmaceutica y procedimiento para su preparacion
IT9019793A0 (it) Composizioni farmaceutiche contenenti ipriflavone,procedimento per la loro preparazione e relativo impiego terapeutico
EE04095B1 (et) Ketoliidide ja nende farmatseutiliselt vastuvõetavate soolade kasutamine farmatseutiliste kompositsioonide valmistamiseks
ITMI951417A0 (it) Composizioni farmaceutiche e procedimento per la loro preparazione
BR9509055A (pt) Imidazoloquinoxalinona uso da mesma e composiçao farmacêutica
AU1447892A (en) Pharmaceutical preparations for the therapy of tumors containing colchicine as the active principle and methods for the use of the same
EE9400182A (et) Peptiidühendid, nende kasutamine, valmistamismeetod ja farmatseutiline segu